Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Lung Function Decline in Early HIV Infection: Impact of Antiretroviral Drug Timing and Drug Regimen.

Kunisaki KM, Baker JV, Collins G, MacDonald DM, Bakowska E, El Filali KM, Nnakelu E, La Rosa A, Connett JE; INSIGHT START Pulmonary Substudy Group.

Am J Respir Crit Care Med. 2019 Dec 16. doi: 10.1164/rccm.201911-2266LE. [Epub ahead of print] No abstract available.

PMID:
31841641
2.

Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial.

Ghazi L, Baker JV, Sharma S, Jain MK, Palfreeman A, Necsoi C, Murray DD, Neaton JD, Drawz PE.

Am J Hypertens. 2020 Jan 1;33(1):43-52. doi: 10.1093/ajh/hpz132.

PMID:
31800000
3.

A Pilot Study of a Mobile App to Support HIV Antiretroviral Therapy Adherence Among Men Who Have Sex with Men Who Use Stimulants.

Horvath KJ, Lammert S, MacLehose RF, Danh T, Baker JV, Carrico AW.

AIDS Behav. 2019 Nov;23(11):3184-3198. doi: 10.1007/s10461-019-02597-3.

PMID:
31309348
4.

Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study.

Castillo-Mancilla JR, Phillips AN, Neaton JD, Neuhaus J, Sharma S, Baker JV, Collins S, Mannheimer S, Pett S, Touzeau-Römer V, Polizzotto MN, Lundgren JD, Gardner EM; INSIGHT START Study Group.

J Int AIDS Soc. 2019 Jun;22(6):e25297. doi: 10.1002/jia2.25297.

5.

Concordance of Self- and Clinician-Collected Anal Swabs to Detect Human Papillomavirus in a Sample of HIV-Negative Men.

Yared NF, Horvath KJ, Baker JV, Thyagarajan B, Waterboer T, Kulasingam S.

J Low Genit Tract Dis. 2019 Jul;23(3):200-204. doi: 10.1097/LGT.0000000000000475.

PMID:
30946259
6.

The Effects of Recombinant Human Lactoferrin on Immune Activation and the Intestinal Microbiome Among Persons Living with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy.

Sortino O, Hullsiek KH, Richards E, Rupert A, Schminke A, Tetekpor N, Quinones M, Prosser R, Schacker T, Sereti I, Baker JV.

J Infect Dis. 2019 May 24;219(12):1963-1968. doi: 10.1093/infdis/jiz042.

PMID:
30721997
7.

Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial.

Boatman JA, Baker JV, Emery S, Furrer H, Mushatt DM, Sedláček D, Lundgren JD, Neaton JD; INSIGHT START Study Group.

J Acquir Immune Defic Syndr. 2019 May 1;81(1):10-17. doi: 10.1097/QAI.0000000000001967.

PMID:
30664075
8.

Associations between baseline biomarkers and lung function in HIV-positive individuals.

MacDonald DM, Zanotto AD, Collins G, Baker JV, Czarnecki M, Loiza E, Nixon DE, Papastamopoulos V, Wendt CH, Wood R, Kunisaki KM; INSIGHT START Pulmonary Substudy Group.

AIDS. 2019 Mar 15;33(4):655-664. doi: 10.1097/QAD.0000000000002101.

PMID:
30601153
9.

Assessing inflammation and its role in comorbidities among persons living with HIV.

Peterson TE, Baker JV.

Curr Opin Infect Dis. 2019 Feb;32(1):8-15. doi: 10.1097/QCO.0000000000000510.

PMID:
30461454
10.

In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus.

Brummel-Ziedins KE, Gissel M, Neuhaus J, Borges ÁH, Chadwick DR, Emery S, Neaton JD, Tracy RP, Baker JV; INSIGHT SMART, ESPRIT Study Groups.

Res Pract Thromb Haemost. 2018 Sep 11;2(4):708-717. doi: 10.1002/rth2.12147. eCollection 2018 Oct.

11.

Inflammation Associates With Impaired Small Arterial Elasticity Early in HIV Disease.

Peterson TE, Huppler Hullsiek K, Wyman Engen N, Kumarasamy N, Lebech AM, Liappis A, Papadopoulos A, Polizzotto MN, Schreiner PJ, Duprez D, Baker JV; INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group.

Open Forum Infect Dis. 2018 May 19;5(6):ofy117. doi: 10.1093/ofid/ofy117. eCollection 2018 Jun 1.

12.

HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome.

Natesampillai S, Cummins NW, Nie Z, Sampath R, Baker JV, Henry K, Pinzone M, O'Doherty U, Polley EC, Bren GD, Katzmann DJ, Badley AD.

J Virol. 2018 Jun 13;92(13). pii: e00037-18. doi: 10.1128/JVI.00037-18. Print 2018 Jul 1.

13.

Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial.

Baker JV, Sharma S, Grund B, Rupert A, Metcalf JA, Schechter M, Munderi P, Aho I, Emery S, Babiker A, Phillips A, Lundgren JD, Neaton JD, Lane HC; INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group.

Open Forum Infect Dis. 2017 Nov 28;4(4):ofx262. doi: 10.1093/ofid/ofx262. eCollection 2017 Fall.

14.

Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study.

Ronit A, Sharma S, Baker JV, Mngqibisa R, Delory T, Caldeira L, Ndembi N, Lundgren JD, Phillips AN; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of Antiretroviral Treatment (START) Study Group.

J Infect Dis. 2018 Jan 17;217(3):405-412. doi: 10.1093/infdis/jix350.

15.

Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.

Cummins NW, Rizza S, Litzow MR, Hua S, Lee GQ, Einkauf K, Chun TW, Rhame F, Baker JV, Busch MP, Chomont N, Dean PG, Fromentin R, Haase AT, Hampton D, Keating SM, Lada SM, Lee TH, Natesampillai S, Richman DD, Schacker TW, Wietgrefe S, Yu XG, Yao JD, Zeuli J, Lichterfeld M, Badley AD.

PLoS Med. 2017 Nov 28;14(11):e1002461. doi: 10.1371/journal.pmed.1002461. eCollection 2017 Nov.

16.

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.

Baker JV, Sharma S, Achhra AC, Bernardino JI, Bogner JR, Duprez D, Emery S, Gazzard B, Gordin J, Grandits G, Phillips AN, Schwarze S, Soliman EZ, Spector SA, Tambussi G, Lundgren J; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group.

J Am Heart Assoc. 2017 May 22;6(5). pii: e004987. doi: 10.1161/JAHA.116.004987.

17.

Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons.

Manion M, Hullsiek KH, Wilson EMP, Rhame F, Kojic E, Gibson D, Hammer J, Patel P, Brooks JT, Baker JV, Sereti I; Study to Understand the Natural History of HIV/AIDS in the Era of Effective Antiretroviral Therapy (the ‘SUN Study’) Investigators.

PLoS One. 2017 May 2;12(5):e0175517. doi: 10.1371/journal.pone.0175517. eCollection 2017.

18.

Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial.

Baker JV, Hullsiek KH, Engen NW, Nelson R, Chetchotisakd P, Gerstoft J, Jessen H, Losso M, Markowitz N, Munderi P, Papadopoulos A, Shuter J, Rappoport C, Pearson MT, Finley E, Babiker A, Emery S, Duprez D; INSIGHT START Arterial Elasticity Substudy Team.

Open Forum Infect Dis. 2016 Oct 8;3(4):ofw213. eCollection 2016 Oct.

19.

Direct and Indirect Effects of Heavy Alcohol Use on Clinical Outcomes in a Longitudinal Study of HIV Patients on ART.

Kahler CW, Liu T, Cioe PA, Bryant V, Pinkston MM, Kojic EM, Onen N, Baker JV, Hammer J, Brooks JT, Patel P.

AIDS Behav. 2017 Jul;21(7):1825-1835. doi: 10.1007/s10461-016-1474-y.

20.

Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.

Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, Cohen CJ, Phillips A, Lundgren JD, Neaton JD; INSIGHT SMART/ESPRIT/SILCAAT Study Group.

PLoS One. 2016 May 12;11(5):e0155100. doi: 10.1371/journal.pone.0155100. eCollection 2016.

21.

Creating Effective Mobile Phone Apps to Optimize Antiretroviral Therapy Adherence: Perspectives From Stimulant-Using HIV-Positive Men Who Have Sex With Men.

Horvath KJ, Alemu D, Danh T, Baker JV, Carrico AW.

JMIR Mhealth Uhealth. 2016 Apr 15;4(2):e48. doi: 10.2196/mhealth.5287.

22.

Immune activation and cardiovascular disease in chronic HIV infection.

Longenecker CT, Sullivan C, Baker JV.

Curr Opin HIV AIDS. 2016 Mar;11(2):216-25. doi: 10.1097/COH.0000000000000227. Review.

23.

Obesity is associated with greater inflammation and monocyte activation among HIV-infected adults receiving antiretroviral therapy.

Conley LJ, Bush TJ, Rupert AW, Sereti I, Patel P, Brooks JT, Baker JV; SUN (Study to Understand the Natural History of HIVAIDS in the Era of Effective Therapy) Investigators.

AIDS. 2015 Oct 23;29(16):2201-7. doi: 10.1097/QAD.0000000000000817.

PMID:
26544583
24.

Sleep Apnea Symptoms as a Predictor of Fatigue in an Urban HIV Clinic.

Goswami U, Baker JV, Wang Q, Khalil W, Kunisaki KM.

AIDS Patient Care STDS. 2015 Nov;29(11):591-6. doi: 10.1089/apc.2015.0079. Epub 2015 Sep 16.

25.

Response to Bandera et al.

Wilson EM, Hullsiek KH, Sereti I, Baker JV.

J Infect Dis. 2015 Sep 1;212(5):841-2. doi: 10.1093/infdis/jiv165. Epub 2015 Mar 19. No abstract available.

26.

Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Baker JV, Engen NW, Huppler Hullsiek K, Stephan C, Jain MK, Munderi P, Pett S, Duprez D; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:109-18. doi: 10.1111/hiv.12239.

27.

CD8+ T-cells count in acute myocardial infarction in HIV disease in a predominantly male cohort.

Badejo OA, Chang CC, So-Armah KA, Tracy RP, Baker JV, Rimland D, Butt AA, Gordon AJ, Rinaldo CR Jr, Kraemer K, Samet JH, Tindle HA, Goetz MB, Rodriguez-Barradas MC, Bedimo R, Gibert CL, Leaf DA, Kuller LH, Deeks SG, Justice AC, Freiberg MS.

Biomed Res Int. 2015;2015:246870. doi: 10.1155/2015/246870. Epub 2015 Jan 19.

28.

HIV infection and cardiovascular disease in women.

Womack JA, Chang CC, So-Armah KA, Alcorn C, Baker JV, Brown ST, Budoff M, Butt AA, Gibert C, Goetz MB, Gottdiener J, Gottlieb S, Justice AC, Leaf D, McGinnis K, Rimland D, Rodriguez-Barradas MC, Sico J, Skanderson M, Tindle H, Tracy RP, Warner A, Freiberg MS.

J Am Heart Assoc. 2014 Oct 16;3(5):e001035. doi: 10.1161/JAHA.114.001035.

29.

HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function.

So-Armah KA, Chang J, Alcorn C, Lo Re V, Baker JV, Tracy R, Butt AA, Agan BK, Rimland D, Gibert CL, Goetz MB, Oursler KK, Rodriguez-Barradas MC, Kuller LH, Brown ST, Stein JH, Skanderson M, Justice AC, Freiberg MS.

Curr HIV Res. 2014;12(1):50-9.

30.

Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease.

Borges ÁH, Weitz JI, Collins G, Baker JV, Lévy Y, Davey RT Jr, Phillips AN, Neaton JD, Lundgren JD, Deeks SG; INSIGHT SILCAAT Scientific Committee.

AIDS. 2014 Jul 31;28(12):1791-6. doi: 10.1097/QAD.0000000000000344.

31.

Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.

Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, Önen NF, Kojic E, Patel P, Brooks JT, Sereti I, Baker JV; Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) Investigators.

J Infect Dis. 2014 Nov 1;210(9):1396-406. doi: 10.1093/infdis/jiu275. Epub 2014 May 9.

32.

Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.

Miller CJ, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek K, Justice AC, Neuhaus J, Paredes R, Petoumenos K, Wentworth D, Winston A, Wolfson J, Neaton JD; INSIGHT SMART Study Group; ESPRIT Study Group.

PLoS One. 2014 Apr 11;9(4):e95061. doi: 10.1371/journal.pone.0095061. eCollection 2014.

33.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

34.

Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort.

Baker JV, Hullsiek KH, Singh A, Wilson E, Henry K, Lichtenstein K, Onen N, Kojic E, Patel P, Brooks JT, Hodis HN, Budoff M, Sereti I; CDC SUN Study Investigators.

AIDS. 2014 Mar 27;28(6):831-40. doi: 10.1097/QAD.0000000000000145.

35.

Does antiretroviral therapy started at high CD4 cell counts reduce an individual HIV-positive patient's disease risk?

Baker JV, Sabin CA.

Curr Opin HIV AIDS. 2014 Jan;9(1):1-3. doi: 10.1097/COH.0000000000000026. No abstract available.

PMID:
24225383
36.

Prehypertension, hypertension, and the risk of acute myocardial infarction in HIV-infected and -uninfected veterans.

Armah KA, Chang CC, Baker JV, Ramachandran VS, Budoff MJ, Crane HM, Gibert CL, Goetz MB, Leaf DA, McGinnis KA, Oursler KK, Rimland D, Rodriguez-Barradas MC, Sico JJ, Warner AL, Hsue PY, Kuller LH, Justice AC, Freiberg MS; Veterans Aging Cohort Study (VACS) Project Team.

Clin Infect Dis. 2014 Jan;58(1):121-9. doi: 10.1093/cid/cit652. Epub 2013 Sep 24.

37.

Chronic HIV disease and activation of the coagulation system.

Baker JV.

Thromb Res. 2013 Nov;132(5):495-9. doi: 10.1016/j.thromres.2013.08.016. Epub 2013 Aug 29. Review.

38.

Human immunodeficiency virus, hepatitis C, and inflammatory biomarkers in individuals with alcohol problems: a cross-sectional study.

Armah KA, Quinn EK, Cheng DM, Tracy RP, Baker JV, Samet JH, Freiberg MS.

BMC Infect Dis. 2013 Aug 29;13:399. doi: 10.1186/1471-2334-13-399.

39.

HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation.

Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D, Cummins N, Dalmau D, DeHovitz J, Lehmann C, Sullivan A, Woolley I, Kuller L, Neaton JD, Tracy RP; INSIGHT SMART Study Team.

J Am Heart Assoc. 2013 Jul 29;2(4):e000264. doi: 10.1161/JAHA.113.000264.

40.

Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients.

Baker JV, Huppler Hullsiek K, Bradford RL, Prosser R, Tracy RP, Key NS.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):367-71. doi: 10.1097/QAI.0b013e3182910121.

41.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

42.

Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection.

Gupta M, Miller CJ, Baker JV, Lazar J, Bogner JR, Calmy A, Soliman EZ, Neaton JD; INSIGHT SMART Study Group.

Am J Cardiol. 2013 Mar 1;111(5):760-4. doi: 10.1016/j.amjcard.2012.11.032. Epub 2012 Dec 29.

43.

Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.

Baker JV, Huppler Hullsiek K, Prosser R, Duprez D, Grimm R, Tracy RP, Rhame F, Henry K, Neaton JD.

PLoS One. 2012;7(10):e46894. doi: 10.1371/journal.pone.0046894. Epub 2012 Oct 17.

44.

Platelet count kinetics following interruption of antiretroviral treatment.

Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group.

AIDS. 2013 Jan 2;27(1):59-68. doi: 10.1097/QAD.0b013e32835a104d.

45.

HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction.

Baker JV, Neuhaus J, Duprez D, Freiberg M, Bernardino JI, Badley AD, Nixon DE, Lundgren JD, Tracy RP, Neaton JD; INSIGHT SMART Study Group.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):128-34. doi: 10.1097/QAI.0b013e318252f99f.

46.

HIV antiretroviral therapy reduces circulating surfactant protein-D levels.

Kunisaki KM, Quick H, Baker JV.

HIV Med. 2011 Oct;12(9):580-1. doi: 10.1111/j.1468-1293.2011.00920.x. No abstract available.

47.

Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort.

Baker JV, Henry WK, Patel P, Bush TJ, Conley LJ, Mack WJ, Overton ET, Budoff M, Hammer J, Carpenter CC, Hodis HN, Brooks JT; Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy Investigators.

Clin Infect Dis. 2011 Oct;53(8):826-35. doi: 10.1093/cid/cir497. Epub 2011 Aug 22.

48.

Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.

Baker JV, Neuhaus J, Duprez D, Cooper DA, Hoy J, Kuller L, Lampe FC, Liappis A, Friis-Moller N, Otvos J, Paton NI, Tracy R, Neaton JD; INSIGHT SMART Study Group.

AIDS. 2011 Nov 13;25(17):2133-42. doi: 10.1097/QAD.0b013e32834be088.

49.

Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.

Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, Bohjanen PR, Novak RM, Neaton JD, Sereti I; INSIGHT Study Group.

J Infect Dis. 2011 Jun 1;203(11):1637-46. doi: 10.1093/infdis/jir134.

50.

If we can't get what we want, can we get what we need? optimizing use of antiretroviral therapy in the current era.

Baker JV, Henry K.

Ann Intern Med. 2011 Apr 19;154(8):563-5. doi: 10.7326/0003-4819-154-8-201104190-00009. No abstract available.

Supplemental Content

Loading ...
Support Center